Authors: De Souza, M.V.N.; Neves Jr., I.; Miranda, G.B.P.; Lourenço, M.C.S.; Vasconcelos, T.A.; Pais, K.C.; Wardell, J.L.; Wardell, S.M.S.V.; Alcântara Jr.; J.P.
Source: Letters in Drug Design & Discovery, v. 3, p. 424-428, 2006.Publisher: Bentham Science
Abstract
A series of eight N-(disubstitutedbenzoyl)isoniazid derivatives have been synthesized and evaluated for their in vitro antibacterial activity against Mycobacterium tuberculosis H37Rv using the alamar blue susceptibility test and the activity expressed as the minimum inhibitory concentration (MIC) in μg/mL. Compounds 15 and 16 exhibited a significant activity (0.5 μg/mL) when compared with first line drugs such as isoniazid (INH) and rifampicin (RIP) and could be a good starting point to develop new lead compounds in the fight against multi-drug resistant tuberculosis.Keywords: Isoniazid, analogs, anti-tubercular activityDocument Type: Research ArticleDOI: http://dx.doi.org/10.2174/157018006777805549Publication date: 1 de Janeiro de 2007
